세포치료용 인간 원료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global cell therapy human raw materials market size is expected to reach USD 22.39 Billion in 2034 from USD 4.83 Billion in 2025, growing at a CAGR of 18.58% during 2026-2034.The global cell therapy human raw materials market is witnessing strong growth driven by increasing research and commercialization of advanced cell-based therapies. Human-derived raw materials such as serum, growth factors, and cell culture media are essential in manufacturing cell therapies. Rising investments in regenerative medicine and immunotherapy are significantly boosting demand.

Major growth drivers include expanding clinical trials, increasing regulatory approvals for cell therapies, and rising focus on personalized medicine. Biopharmaceutical companies are strengthening supply chains to ensure high-quality and compliant raw materials. Growing collaborations between research institutions and industry players are further supporting market development.

In the future, advancements in manufacturing technologies and increasing commercialization of CAR-T and stem cell therapies will create significant opportunities. As demand for innovative biologics rises, the cell therapy human raw materials market is expected to expand steadily across global healthcare sectors.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Cell Culture Media
• Cell Culture Sera
• Cell Culture Supplements
• Reagents & Buffers
• Other Raw Materials

By End-Use

• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutions

COMPANIES PROFILED

• Thermo Fisher Scientific Inc., Merck KGaA, Actylis, ACROBiosystems, STEMCELL Technologies Inc., Grifols S.A., Charles River Laboratories International Inc., RoosterBio Inc., PromoCell GmbH, Danaher Corporation, BioIVT LLC, GeminiBio (Gemini Bioproducts LLC), Akron Biotech, AllCells LLC, CGT Global

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Cell Culture Media Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Cell Culture Sera Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cell Culture Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Reagents & Buffers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Raw Materials Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Biopharmaceutical & Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. CROs & CMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Academic & Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CELL THERAPY HUMAN RAW MATERIALS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Thermo Fisher Scientific Inc
  • 8.2.2 Merck KGaA
  • 8.2.3 Actylis
  • 8.2.4 ACROBiosystems
  • 8.2.5 STEMCELL Technologies Inc
  • 8.2.6 Grifols S.A
  • 8.2.7 Charles River Laboratories International Inc
  • 8.2.8 RoosterBio Inc
  • 8.2.9 PromoCell GmbH
  • 8.2.10 Danaher Corporation
  • 8.2.11 BioIVT LLC
  • 8.2.12 GeminiBio (Gemini Bioproducts LLC)
  • 8.2.13 Akron Biotech
  • 8.2.14 AllCells LLC
  • 8.2.15 CGT Global